To include your compound in the COVID-19 Resource Center, submit it here.

Lilly, Incyte to resubmit Olumiant NDA in January

Eli Lilly and Co. (NYSE:LLY) said it plans to resubmit an NDA for Olumiant baricitinib to treat rheumatoid

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE